Pembrolizumab Use: Indications, Dosing, Monitoring, and Toxicity Management
Approved Indications
Pembrolizumab is FDA-approved for multiple solid tumors and one hematologic malignancy, with indications expanding to include tissue-agnostic approvals based on biomarkers. 1, 2
Key FDA-approved indications include:
- Melanoma (metastatic/advanced)
- Non-small cell lung cancer (NSCLC) - first-line for PD-L1 TPS ≥50% (without EGFR/ALK alterations) and second-line for PD-L1 TPS ≥1% after platinum-based chemotherapy 3
- Urothelial carcinoma (locally advanced/metastatic) - after platinum-containing chemotherapy or within 12 months of neoadjuvant/adjuvant platinum therapy 1
- Head and neck squamous cell carcinoma - recurrent/metastatic with progression on/after platinum-based therapy 1
- Classical Hodgkin lymphoma - refractory or relapsed after ≥3 prior lines of therapy 1
- MSI-H or dMMR tumors (tissue-agnostic) - unresectable/metastatic disease progressing after prior treatment with no satisfactory alternatives, or MSI-H/dMMR colorectal cancer after fluoropyrimidine, oxaliplatin, and irinotecan 1, 2
Recommended Dosing
The standard pembrolizumab dose is 200 mg IV every 3 weeks or 400 mg IV every 6 weeks, administered as an intravenous infusion. 4
Dosing considerations:
- 200 mg flat dose every 3 weeks was established in the KEYNOTE-024 trial for first-line NSCLC 1
- 400 mg every 6 weeks is an FDA-approved alternative based on population pharmacokinetic modeling 5
- Earlier trials used weight-based dosing (2 mg/kg or 10 mg/kg), but flat dosing is now standard 1
- Recent evidence suggests weight-based dosing may be cost-effective without compromising safety or efficacy 6
- Caution with dosing switches: Patients with high intercycle variability in maximum concentration during Q3W dosing show increased risk of immune-related adverse events when switching to Q6W, particularly pneumonitis 5
Monitoring Requirements
Monitor for immune-related adverse events at every visit with specific attention to organ-specific toxicities, as irAEs can occur early (within weeks) or delayed (up to 1 year after discontinuation). 1
Baseline Assessment
- Complete blood count, comprehensive metabolic panel (liver and renal function)
- Thyroid function tests (TSH, free T4)
- Baseline cortisol if endocrine symptoms present
- Pregnancy test in women of childbearing potential
Ongoing Monitoring
- At each infusion: Clinical assessment for new symptoms (rash, diarrhea, dyspnea, fatigue, endocrine symptoms)
- Every 4-6 weeks: Liver function tests, thyroid function tests, creatinine
- As clinically indicated: Imaging for pneumonitis if respiratory symptoms develop; tissue biopsy for grade 3-4 toxicities when diagnostic uncertainty exists 1
Timing of irAE Onset
- Skin toxicities: Median onset 5.6 weeks (range 0.1-55 weeks) 1
- Gastrointestinal: Median onset 26.3 weeks (range 13.1-57 weeks) 1
- Hepatic: Median onset 7.4 weeks (range 2.1-48 weeks) 1
- Endocrine: Median onset 28.6 weeks (range 19.1-38.1 weeks) 1
- Pulmonary: Median onset 6.7 weeks 1
Immune-Related Adverse Events: Incidence and Severity
Treatment-related adverse events occur in 63-80% of patients on pembrolizumab monotherapy, with grade 3-4 toxicities in 10-16% of patients. 1
Key toxicity data from pivotal trials:
- KEYNOTE-006 (melanoma): 73-80% any-grade AEs, 10-13.5% grade ≥3 1
- KEYNOTE-010 (NSCLC): 63-66% any-grade AEs, 13-16% grade 3-4 1
- KEYNOTE-024 (first-line NSCLC): 73.4% any-grade AEs, 26.6% grade ≥3 1
Most common irAEs include: fatigue, rash, diarrhea, fever, decreased appetite, itching, nausea, hypothyroidism 4
Management of Immune-Related Adverse Events
Early recognition and prompt intervention with immune suppression is critical; hold pembrolizumab for grade 2-3 toxicities and permanently discontinue for grade 4 or recurrent grade 3 irAEs. 1, 2, 7
General Management Algorithm
Grade 1 (Mild)
- Continue pembrolizumab
- Monitor closely at each visit
- Symptomatic management
Grade 2 (Moderate)
- Hold pembrolizumab until toxicity resolves to grade ≤1
- Consider corticosteroids (prednisone 0.5-1 mg/kg/day or equivalent) for persistent symptoms
- Resume pembrolizumab when improved to grade ≤1
Grade 3 (Severe)
- Hold pembrolizumab permanently (consider resumption only after resolution to grade ≤1 and case-by-case assessment)
- Initiate corticosteroids: prednisone 1-2 mg/kg/day or methylprednisolone IV equivalent 1, 7
- Taper steroids over ≥4 weeks once improved
- Add steroid-sparing immunosuppressants (infliximab, mycophenolate) if no improvement within 3-5 days
Grade 4 (Life-threatening)
- Permanently discontinue pembrolizumab
- High-dose IV corticosteroids: methylprednisolone 1-2 mg/kg/day 7
- Consider additional immunosuppression immediately
- Hospitalize for close monitoring
Organ-Specific Management Considerations
Pneumonitis (potentially life-threatening):
- Hold pembrolizumab for grade 2, permanently discontinue for grade 3-4
- CT chest to confirm diagnosis
- Prednisone 1-2 mg/kg/day for grade 2-4 7
- High intercycle concentration variability increases pneumonitis risk after dose switching 5
Colitis/Diarrhea:
- Hold for grade 2-3, discontinue for grade 4
- Prednisone 1-2 mg/kg/day for grade ≥2
- Consider infliximab 5 mg/kg if no improvement in 3-5 days (avoid if hepatotoxicity present) 7
Hepatitis:
- Hold for grade 2 (AST/ALT 3-5× ULN), discontinue for grade 3-4 (>5× ULN)
- Prednisone 0.5-1 mg/kg/day for grade 2,1-2 mg/kg/day for grade ≥3 7
- Liver biopsy may guide optimal corticosteroid dosing: histopathological severity assessment allows individualized therapy (e.g., prednisolone 0.3 mg/kg/day for moderate inflammation) 8
- Monitor for hepatitis B reactivation in patients with resolved HBV 8
Endocrinopathies (thyroid, hypophysitis, adrenal insufficiency):
- Most endocrine irAEs are permanent and require lifelong hormone replacement
- Hypothyroidism: levothyroxine replacement, continue pembrolizumab
- Hypophysitis/adrenal insufficiency: physiologic corticosteroid replacement (hydrocortisone 15-25 mg/day in divided doses), may continue pembrolizumab if stable 7
Dermatologic toxicities:
- Continue pembrolizumab for grade 1-2 with topical corticosteroids
- Hold for grade 3, discontinue for grade 4 or Stevens-Johnson syndrome/toxic epidermal necrolysis
- Rare presentations like morphea may require methotrexate and topical corticosteroids 9
Critical Pitfalls to Avoid
- Do not delay corticosteroids for grade ≥2 irAEs while awaiting specialist consultation; early intervention prevents progression 2, 7
- Do not use infliximab for hepatotoxicity due to risk of worsening liver injury 7
- Do not assume all toxicities are immune-related: consider infection, disease progression, or other etiologies, particularly in atypical presentations 1
- Do not abruptly stop corticosteroids: taper over ≥4 weeks to prevent rebound inflammation 7
- Treatment-related deaths occur in up to 2% of patients, emphasizing the importance of vigilant monitoring 2